A Proteomics Pipeline for Generating Clinical Grade Biomarker Candidates from Data‐Independent Acquisition Mass Spectrometry (DIA‐MS) Discovery
Angewandte Chemie International Edition · 20.12.2024 · 63 (52)
DOI: 10.1002/anie.202409446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 11.11.2024. Verfasst von Qin Fu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cedars Sinai Medical Center, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Proteomics, Biomarkers, Mass Spectrometry. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Institute of Health, NIDDK NIH HHS, Leona M. and Harry B. Helmsley Charitable Trust.
Abstract (Originalsprache)
Clinical biomarker development has been stymied by inaccurate protein quantification from mass spectrometry (MS) discovery data and a prolonged validation process. To mitigate these issues, we created the Targeted Extraction Assessment of Quantification (TEAQ) software package that uses data‐independent acquisition analysis from a discovery cohort to select precursors, peptides, and proteins that adhere to analytical criteria required for established targeted assays. TEAQ was applied to DIA‐MS data from plasma samples acquired on a new high resolution accurate mass (HRAM) mass spectrometry platform where precursors were evaluated for linearity, specificity, repeatability, reproducibility, and intra‐protein correlation based on 8‐ or 11‐point loading curves at three throughputs. This data can be used as a general resource for developing other targeted assays. TEAQ analysis of data from a case and control cohort for inflammatory bowel disease ( n =492) identified 1110 signature peptides for 326 quantifiable proteins from the 1179 identified proteins. Applying TEAQ analysis to discovery data will streamline targeted assay development and the transition to validation and clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cedars Sinai Medical Center, Los Angeles, CA, USA.
- Thermo Fisher Scientific, Bremen, Germany.
ORCID-Profile: Qin Fu
Förderung
- National Institute of Health
- NIDDK NIH HHS
- Leona M. and Harry B. Helmsley Charitable Trust
- Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute
- Cedars-Sinai Precision Health Initiative
- Erika J. Glazer Family Foundation
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Fu, Q., Vegesna, M., Sundararaman, N., Damoc, E., Arrey, T. N., Pashkova, A., Mengesha, E., Debbas, P., Joung, S., Li, D., Cheng, S., Braun, J., McGovern, D. P. B., Murray, C. I., Xuan, Y., & Van Eyk, J. E. (2024). A Proteomics Pipeline for Generating Clinical Grade Biomarker Candidates from Data‐Independent Acquisition Mass Spectrometry (DIA‐MS) Discovery. Angewandte Chemie International Edition, 63(52). https://doi.org/10.1002/anie.202409446
Vancouver
Fu Q, Vegesna M, Sundararaman N, Damoc E, Arrey TN, Pashkova A, et al. A Proteomics Pipeline for Generating Clinical Grade Biomarker Candidates from Data‐Independent Acquisition Mass Spectrometry (DIA‐MS) Discovery. Angewandte Chemie International Edition. 2024;63(52). doi:10.1002/anie.202409446
BibTeX
@article{Fu2024,
author = {Fu, Qin and Vegesna, Manasa and Sundararaman, Niveda and Damoc, Eugen and Arrey, Tabiwang N and Pashkova, Anna and Mengesha, Emebet and Debbas, Philip and Joung, Sandy and Li, Dalin and Cheng, Susan and Braun, Jonathan and McGovern, Dermot P B and Murray, Christopher I and Xuan, Yue and Van Eyk, Jennifer E},
title = {A Proteomics Pipeline for Generating Clinical Grade Biomarker Candidates from Data‐Independent Acquisition Mass Spectrometry (DIA‐MS) Discovery},
journal = {Angewandte Chemie International Edition},
year = {2024},
volume = {63},
number = {52},
doi = {10.1002/anie.202409446}
}
EUVIMED